Education
About Us
Working with TipRanks
Follow Us
Azenta, Inc. (AZTA)
NASDAQ:AZTA
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.12Last Year’s EPS
0.05Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a balanced picture: management reaffirmed full-year guidance, highlighted strong cash, active capital allocation (including a $250M buyback authorization), and clear operational initiatives (ABS, Kaizen, regionalization) that support a planned margin and revenue ramp in the back half. However, near-term results show meaningful margin compression (gross margin down ~360 bps, adjusted EBITDA margin down ~230 bps), automated store quality remediation costs ($3M–$5M), North American softness and a meaningful decline in Sanger sequencing. Given the mix of strategic positives and notable near-term headwinds, the tone is cautiously optimistic but tempered by execution and macro risks.Company Guidance
Total Revenue and Organic Trend
Total revenue of $149 million for Q1 FY2026, up 1% reported and down ~1% organically with a ~2% foreign exchange headwind.
Strong Cash Position and Capital Authorization
Ended the quarter with $571 million in cash, cash equivalents, and marketable securities (up $25 million QoQ), no debt outstanding, and a $250 million share repurchase authorization approved by the Board.
Segment Strengths — Multiomics and Biorepositories
Multiomics revenue $67 million (flat organic), driven by growth in next-generation sequencing and gene synthesis; Sample Management Solutions biorepositories showed solid growth. China delivered strong 26% organic growth in Multiomics.
Profitability and Cash Generation (Non-GAAP)
Non-GAAP EPS of $0.09 and adjusted EBITDA of approximately $13 million (8.5% margin). Free cash flow (including B Medical) was $15 million for the quarter.
Reaffirmed Full-Year Guidance
Management reaffirmed FY2026 targets: 3%–5% organic revenue growth, ~300 basis points of adjusted EBITDA margin expansion, and >30% year-over-year improvement in free cash flow generation.
Operational Improvement Initiatives
Continued deployment of the Azenta Business System (ABS), Kaizen routines, decentralized operating model, and targeted investments in biorepositories, regionalized gene synthesis, automation, and commercialization to drive productivity and margin expansion.
Strategic Portfolio Actions
Definitive agreement to sell B Medical (treated as discontinued operations) expected to close on or before March 31, 2026; recorded a $10 million non-cash loss related to assets held for sale. Management signals active M&A funnel and disciplined capital allocation.
AZTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AZTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $36.91 | $28.49 | -22.81% |
Nov 21, 2025 | $30.00 | $34.89 | +16.30% |
Aug 05, 2025 | $32.41 | $26.90 | -17.00% |
May 07, 2025 | $25.42 | $25.26 | -0.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Azenta, Inc. (AZTA) report earnings?
Azenta, Inc. (AZTA) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is Azenta, Inc. (AZTA) earnings time?
Azenta, Inc. (AZTA) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AZTA EPS forecast?
AZTA EPS forecast for the fiscal quarter 2026 (Q2) is 0.12.
